The market for influenza vaccines in the United States will at some point rebound, one of the manufacturers of the shot predicted on Nov. 4.
“When you overlay the hospitalization trends, what you see is a clear correlation between the reduced immunization rates and the higher disease burden,” Dave Ross, senior vice president and general manager of CSL Seqirus, told investors.
